The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Human CD4+CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells
Open accessAbstract
Summary: While murine CD4+CD39+ regulatory T cells (Treg) co-express CD73 and hydrolyze exogenous (e) adenosine triphosphate (ATP) to immunosuppressive adenosine (ADO), surface co-expression of CD73 on human circulating CD4+CD39+Treg is rare. Therefore, the ability of human Treg to produce and utilize ADO for suppression remains unclear. Using mass spectrometry, we measured nucleoside production by subsets of human CD4+CD39+ and CD4+CD39(–)CD73+T cells or CD19+B cells isolated from blood of 30 volunteers and 14 cancer patients. CD39 and CD73 expression was evaluated by flow cytometry, Western blots, confocal microscopy or reverse transcription–polymerase chain reaction (RT–PCR). Circulating CD4+CD39+Treg which hydrolyzed eATP to 5′-AMP contained few intracytoplasmic granules and had low CD73 mRNA levels. Only ∼1% of these Treg were CD39+CD73+. In contrast, CD4+CD39negCD73+T cells contained numerous CD73+ granules in the cytoplasm and strongly expressed surface CD73. In vitro-generated Treg (Tr1) and most B cells were CD39+CD73+. All these CD73+T cell subsets and B cells hydrolyzed 5′-AMP to ADO. Exosomes isolated from plasma of normal control (NC) or cancer patients carried enzymatically active CD39 and CD73+ and, when supplied with eATP, hydrolyzed it to ADO. Only CD4+CD39+Treg co-incubated with CD4+CD73+T cells, B cells or CD39+CD73+ exosomes produced ADO. Thus, contact with membrane-tethered CD73 was sufficient for ADO production by CD4+CD39+Treg. In microenvironments containing CD4+CD73+T cells, B cells or CD39+CD73+ exosomes, CD73 is readily available to CD4+CD39+CD73negTreg for the production of immunosuppressive ADO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Adenosine, an endogenous distress signal, modulates tissue damage and repair
Fredholm, B. B. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402132 · Cited by 686
Regulatory T cells: recommendations to simplify the nomenclature
Abbas, A. K., Benoist, C., Bluestone, J. A., Campbell, D. J., Ghosh, S., Hori, S., Jiang, S., Kuchroo, V. K., Mathis, D., Roncarolo, M. G., et al. (2013) · Nature Immunology · doi:10.1038/ni.2554 · Cited by 623
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 572
Rogosch, T., Kerzel, S., Hoi, K. H., Zhang, Z., Maier, R. F., Ippolito, G. C., & Zemlin, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00176 · Cited by 555
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Buckley, R. H. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104614 · Cited by 532
Zarek, P. E., Huang, C.-T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J., Drake, C. G., & Powell, J. D. (2008) · Blood · doi:10.1182/blood-2007-03-081646 · Cited by 515
Cited by
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Tumor-Derived Exosomes and Their Role in Cancer Progression
(2016) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2015.12.005 · Cited by 755
Exosomes and their roles in immune regulation and cancer
Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.02.009 · Cited by 597
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Exosomes and tumor-mediated immune suppression
Whiteside, T. L. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81136 · Cited by 569
Self-citationChaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Ludwig, S., Floros, T., Theodoraki, M.-N., Hong, C.-S., Jackson, E. K., Lang, S., & Whiteside, T. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2819 · Cited by 334
Self-citationTumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets
Muller, L., Mitsuhashi, M., Simms, P., Gooding, W. E., & Whiteside, T. L. (2016) · Scientific Reports · doi:10.1038/srep20254 · Cited by 309
Self-citationImmunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity
Vignali, P. D. A., DePeaux, K., Watson, M. J., Ye, C., Ford, B. R., Lontos, K., McGaa, N. K., Scharping, N. E., Menk, A. V., Robson, S. C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01379-9 · Cited by 269
Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
Nam, G., Choi, Y., Kim, G. B., Kim, S., Kim, S. A., & Kim, I. (2020) · Advanced Materials · doi:10.1002/adma.202002440 · Cited by 267
Information transfer by exosomes: A new frontier in hematologic malignancies
Boyiadzis, M., & Whiteside, T. L. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.01.004 · Cited by 79
Self-citationNoble, A., Pring, E. T., Durant, L., Man, R., Dilke, S. M., Hoyles, L., James, S. A., Carding, S. R., Jenkins, J. T., & Knight, S. C. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03135-8 · Cited by 34
Metadata
- Authors
- Schuler, P. J., Saze, Z., Hong, C.-S., Muller, L., Gillespie, D. G., Cheng, D., Harasymczuk, M., Mandapathil, M., Lang, S., Jackson, E. K., & Whiteside, T. L.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07-09
- Volume
- 177
- Issue
- 2
- Pages
- 531-543
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W1705652018
- Cited by
- 277
- References
- 41
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.